Production and characterisation of recombinant human chaperonin 10 for treatment of inflammatory disease

Naylor, Dean J., Hunt, Ben, Guidolin, Angelo, Hey, Allan W., Bastiras, Stan, de Bakker, Christopher J., Chin, David Y., Marquis, Christopher P., Lambert, Daniel, Howard, Christopher B., Dobbin, Caroline A. and Mahler, Stephen M. (2015) Production and characterisation of recombinant human chaperonin 10 for treatment of inflammatory disease. Process Biochemistry, 50 10: 1669-1679. doi:10.1016/j.procbio.2015.06.022

Attached Files (Some files may be inaccessible until you login with your UQ eSpace credentials)
Name Description MIMEType Size Downloads
UQ365564_OA.pdf Full text (open access) application/pdf 851.73KB 0

Author Naylor, Dean J.
Hunt, Ben
Guidolin, Angelo
Hey, Allan W.
Bastiras, Stan
de Bakker, Christopher J.
Chin, David Y.
Marquis, Christopher P.
Lambert, Daniel
Howard, Christopher B.
Dobbin, Caroline A.
Mahler, Stephen M.
Title Production and characterisation of recombinant human chaperonin 10 for treatment of inflammatory disease
Journal name Process Biochemistry   Check publisher's open access policy
ISSN 1359-5113
Publication date 2015-05-13
Year available 2015
Sub-type Article (original research)
DOI 10.1016/j.procbio.2015.06.022
Open Access Status File (Author Post-print)
Volume 50
Issue 10
Start page 1669
End page 1679
Total pages 11
Place of publication London, United Kingdom
Publisher Elsevier
Language eng
Formatted abstract
Human chaperonin 10 (Cpn10) and chaperonin 60 (Cpn60) fulfil an essential role in mitochondrial protein folding. Cpn10 is located in the mitochondrial matrix; however, it has also been detected in extra-mitochondrial compartments where it has demonstrated anti-inflammatory and immunoregulatory activity, suggesting a potential therapeutic value for the treatment of inflammatory and autoimmune disorders that corresponds with its recently proposed role as a resolution-associated molecular patterns (RAMPs) molecule. Ala-Cpn10, a recombinant, minimally modified Cpn10 synthesised in Escherichia coli, is formulated for use in clinical trials and pre-clinical studies with intravenous or subcutaneous administration. Herein, we report the development of a bioprocess for the production of ∼115 g of recombinant human Ala-Cpn10 from a 100 L E. coli fermentation with >99% purity (SDS-PAGE), <0.6 EU mg−1 endotoxin, <18 pg mg−1 DNA and 3.2% molecular variants. This bioprocess was achieved through a careful optimisation of the gene construct, the promoter system and the fermentation process. Recombinant Ala-Cpn10 produced in this process is active as a molecular chaperone indicating correct tertiary and quaternary structure and the stability profile indicates no significant changes with storage as a liquid for at least 3 years at 2–8 °C. The results of validated characterisation assays demonstrate that purified Ala-Cpn10 produced using the optimised process reported here is suitable for its intended purpose as an investigational drug product, and this material is currently being tested in a phase II study for efficacy, safety and impact on biomarkers in subjects with mildly active Systemic Lupus Erythematosus (SLE) under US IND 116156.
Keyword Cpn10
Systemic Lupus Erythematosus (SLE)
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ
Additional Notes In Press, Corrected Proof

Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 0 times in Thomson Reuters Web of Science Article
Scopus Citation Count Cited 0 times in Scopus Article
Google Scholar Search Google Scholar
Created: Tue, 28 Jul 2015, 10:44:42 EST by System User on behalf of Scholarly Communication and Digitisation Service